Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) (TICS-DM)
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study
Sponsor: AstraZeneca
A PHASE4 clinical study on Coronary Artery Disease and Diabetes Mellitus. Type 2, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE4
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Spanish Society of Cardiology
For direct contact, visit the study record on ClinicalTrials.gov .